Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CBL0137 + Gemcitabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CBL0137||CBL 0137|CBL-0137||CBL0137 is a curaxin compound that binds to and inhibits the facilitates chromatin transcription (FACT) complex, resulting in apoptosis in cancer cells (PMID: 25402820) and also disrupts DNA and histone interactions (PMID: 30926878, PMID: 32631516, PMID: 32202904).|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 14||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|